J&J Medical Connect
BALVERSA®

(erdafitinib)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

BALVERSA® (erdafitinib)
Medical Information

BALVERSA - ANNAR Study

Last Updated: 06/18/2025

SUMMARY

  • ANNAR (NCT03955913) is a prospective, non-interventional study to identify adult patients with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue and to assess eligibility status for BALVERSA studies. The primary data source for this study will be the patients’ medical records. Results from the ANNAR study have not been published. The study has enrolled 3679 patients from 199 study sites.1 For complete study details, refer to https://clinicaltrials.gov/study/NCT03955913.

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) conducted on 16 June 2025 did not identify any relevant citations pertaining to this topic.

 

References

Show
1 Janssen Research & Development LLC. A study to identify participants with urothelial cancer and fibroblast growth factor receptor gene aberrations. In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 June 16]. Available from: https://clinicaltrials.gov/study/NCT03955913 NLM Identifier: NCT03955913.  

Would you like to clear and leave your conversation? Message history will be lost.